These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 20091252)

  • 41. Ventricular arrhythmias: from risk assessment for sudden cardiac death to therapeutic intervention.
    Wissner E; Kuck KH
    Herz; 2009 Nov; 34(7):503-4. PubMed ID: 20091249
    [No Abstract]   [Full Text] [Related]  

  • 42. [Is an electrophysiological study always necessary before defibrillator implantation?].
    Bänsch D; Antz M
    Herz; 2005 Mar; 30(2):119-22. PubMed ID: 15875100
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.
    Hilleman DE; Bauman AL
    Pharmacotherapy; 2001 May; 21(5):556-75. PubMed ID: 11349745
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study.
    Bellocci F; Biasucci LM; Gensini GF; Padeletti L; Raviele A; Santini M; Giubilato G; Landolina M; Biondi-Zoccai G; Raciti G; Sassara M; Castro A; Kheir A; Crea F
    J Cardiovasc Med (Hagerstown); 2007 Apr; 8(4):293-9. PubMed ID: 17413310
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sex Differences in Device Therapies for Ventricular Arrhythmias or Death in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) Trial.
    Tompkins CM; Kutyifa V; Arshad A; McNitt S; Polonsky B; Wang PJ; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):862-871. PubMed ID: 25929699
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in patients with left ventricular systolic dysfunction: 14 years after MADIT.
    Franqui-Rivera H; Sotomonte JC
    P R Health Sci J; 2011 Jun; 30(2):78-83. PubMed ID: 21682151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Arrhythmogenic Right Ventricular Cardiomyopathy: Risk Stratification and Indications for Defibrillator Therapy.
    Zorzi A; Rigato I; Bauce B; Pilichou K; Basso C; Thiene G; Iliceto S; Corrado D
    Curr Cardiol Rep; 2016 Jun; 18(6):57. PubMed ID: 27147509
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge.
    Weissler-Snir A; Adler A; Williams L; Gruner C; Rakowski H
    Eur Heart J; 2017 Jun; 38(22):1728-1737. PubMed ID: 27371714
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
    Thavikulwat AC; Tomson TT; Knight BP; Bonow RO; Choudhury L
    J Cardiovasc Electrophysiol; 2016 Aug; 27(8):953-60. PubMed ID: 27138377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ventricular tachycardia and sudden cardiac death.
    Reddy PC; Tandon N; Stafford PR
    J La State Med Soc; 1999 May; 151(5):281-7. PubMed ID: 10363484
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Left ventricular sphericity independently predicts appropriate implantable cardioverter-defibrillator therapy.
    Levine YC; Matos J; Rosenberg MA; Manning WJ; Josephson ME; Buxton AE
    Heart Rhythm; 2016 Feb; 13(2):490-7. PubMed ID: 26409099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Microvolt T-wave alternans and autonomic nervous system parameters can be helpful in the identification of low-arrhythmic risk patients with ischemic left ventricular systolic dysfunction.
    Daniłowicz-Szymanowicz L; Kaufmann D; Rozwadowska K; Kempa M; Lewicka E; Raczak G
    PLoS One; 2018; 13(5):e0196812. PubMed ID: 29723261
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of nonsustained ventricular tachycardia and programmed ventricular stimulation for risk stratification in patients with idiopathic dilated cardiomyopathy.
    Becker R; Haass M; Ick D; Krueger C; Bauer A; Senges-Becker JC; Voss F; Hilbel T; Niroomand F; Katus HA; Schoels W
    Basic Res Cardiol; 2003 Jul; 98(4):259-66. PubMed ID: 12835955
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Amino-terminal pro-brain natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillators.
    Manios EG; Kallergis EM; Kanoupakis EM; Mavrakis HE; Kambouraki DC; Arfanakis DA; Vardas PE
    Chest; 2005 Oct; 128(4):2604-10. PubMed ID: 16236931
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improving sudden cardiac death risk stratification by evaluating electrocardiographic measures of global electrical heterogeneity and clinical outcomes among patients with implantable cardioverter-defibrillators: rationale and design for a retrospective, multicenter, cohort study.
    Waks JW; Hamilton C; Das S; Ehdaie A; Minnier J; Narayan S; Niebauer M; Raitt M; Tompkins C; Varma N; Chugh S; Tereshchenko LG
    J Interv Card Electrophysiol; 2018 Jun; 52(1):77-89. PubMed ID: 29541969
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk Stratification for Sudden Cardiac Death in Non-Ischaemic Dilated Cardiomyopathy.
    Akhtar M; Elliott PM
    Curr Cardiol Rep; 2019 Nov; 21(12):155. PubMed ID: 31768884
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy.
    Maron BJ; Maron MS
    Heart Rhythm; 2016 May; 13(5):1155-1165. PubMed ID: 26749314
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Utilization of implantable cardioverter-defibrillators for the prevention of sudden cardiac death in emerging countries: Improve SCA clinical trial.
    Zhang S; Ching CK; Huang D; Liu YB; Rodriguez-Guerrero DA; Hussin A; Kim YH; Chasnoits AR; Cerkvenik J; Lexcen DR; Muckala K; Brown ML; Cheng A; Singh B;
    Heart Rhythm; 2020 Mar; 17(3):468-475. PubMed ID: 31561030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiac magnetic resonance imaging and primary prevention implantable cardioverter defibrillator therapy: current recommendations and future directions.
    Guaricci AI; De Santis D; Rabbat MG; Pontone G
    J Cardiovasc Med (Hagerstown); 2018 May; 19(5):223-228. PubMed ID: 29561311
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ
    Circ J; 2010 Nov; 74(11):2271-82. PubMed ID: 20962423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.